公开(公告)号：US20250144178A1

公开(公告)日：2025-05-08

申请号：US18836703

申请日：2023-02-10

Applicant: KANAPH THERAPEUTICS INC.

Inventor： Dongsu Kim ,  Donggeon Kim ,  Hyunji Lee ,  Yujin Yoon ,  Youngin Lee ,  Dahea Lee ,  Jihoon Chang ,  Byoung Chul Lee

IPC: A61K38/20 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/675 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00

Abstract: The present invention provides a combined therapeutic agent of: a fusion protein comprising IL-12 or a variant thereof and an antigen-binding site that specifically binds to FAP; and an anticancer agent. The bispecific antibody exhibits an anticancer effect by IL-12 and in particular, when the anti-FAP antibody is realized in one antibody, cancer can be efficiently treated by targeting FAP expressed highly specifically in a tumor and specifically localizing IL-12 to a tumor site. When the fusion protein is administered in combination with a known anticancer agent, there is a synergistic effect on anticancer treatment.